Hanson Wade Intelligence

RNA Therapy: The Delivery Dilemma and the Quest for a Breakthrough   As the initial buzz around RNA therapies from 2020 subsides, their impact continues to make waves. Exciting developments, such as the 2024 collaboration between UT Southwestern Medical Center, Pfizer and Boehringer Ingelheim's potential $2 billion deal with Suzhou Ribo Life Science Co., Ltd involving RIBO-GalSTAR, showcase the enduring promise of RNA technology while bringing to light the ongoing focus on RNA delivery.   Despite the strides made, issues with non-viral and viral systems—including instability, inefficient cellular uptake, safety concerns, and payload size—remain significant obstacles. However, it's encouraging to see continued investment aimed at overcoming these hurdles. This ongoing progress has led Hanson Wade Intelligence to ask: How have these advancements shaped the field, and how is the focus shifting across different technologies?   To stay ahead of the curve with indication landscapes, opportunity assessments, or other custom researches, visit our website at https://lnkd.in/e9yRCP4U   Or   Drop us an email at: [email protected]   The analysis below was made possible with access to Beacon database.   #RNAtherapy #RNAdelivery #mRNA #BiotechInnovation #BiotechTrends #MedicalResearch #HealthcareInnovation #Biopharma #lifescience   To stay ahead of the curve with indication landscapes, opportunity assessments, or other custom researches, visit our website at https://lnkd.in/e9yRCP4U

Last week, WuXi XDC published its 2024 H1 report, which showed significant growth in its revenue and profit. More notably, the drug conjugate specialist CRDMO is currently partnering with ADC developers for over 600 research and preclinical assets. 🚀 The surge in ADC (Anything Drug-Conjugate) preclinical activities in recent years is nothing short of remarkable! The ADC pipeline is expanding rapidly, with a staggering 41% CAGR over the past five years. What’s driving this unprecedented growth? ·      Advances in Linker Chemistry & Next-Gen Payloads: Cutting-edge innovations in linker technology and potent payloads are enhancing the precision and efficacy of ADCs, making them more powerful than ever. ·      Rising Demand for Precision Medicines: The global shift towards personalized healthcare is fueling the need for targeted therapies like ADCs, which can deliver potent drugs directly to cancer cells while minimizing off-target effects. ·      Regulatory Successes: Recent approvals, such as the pan-indication approval for ENHERTU, are validating the ADC approach and encouraging more research and development in this space. ·      Increased Investment: Both established pharma companies and biotech startups are pouring resources into ADC research, driving a wave of new preclinical studies. As ADC technology continues to evolve, we're witnessing a transformative era in targeted cancer therapy and beyond!🧬 Follow our page for more life science market insights, or visit our website at: https://lnkd.in/e9yRCP4U If you need support with your market strategy, speak to the Hanson Wade Intelligence team at [email protected] This analysis was made possible with Beacon ADC database #Pharmaceuticals #Biotech #Oncology #PrecisionMedicine #ADC #DrugDevelopment #CancerResearch #HealthcareInnovation #Lifescience #marketresearch #drugdevelopment #pharmaintelligence

🚨FINAL CALL🚨 : Join us for an insightful webinar focused on accelerating mRNA production through leveraging synthetic DNA for enhanced IVT efficiency and rapid delivery 📅 Date: 28 August 🕒 Time: 12 PM ET (6 PM CEST).   🌟 Hosted by Hanson Wade and Syngoi, featuring leading speakers from Syngoi Technologies, Quantoom Biosciences, Recipharm, Afrigen Biologics (Pty) Ltd   👩💼👨💼 Discover the latest innovations in mRNA production and how synthetic DNA technology is revolutionizing efficiency IVT.   Register now to secure your spot (it's free)! https://lnkd.in/dndj_KyW   #Webinar #mRNA #SyntheticDNA #Biotechnology #Innovation #mRNAproduction

⏰ ONE WEEK TO GO! ⏰ 🌐🔬 Join us and Syngoi for an exciting webinar - "Accelerating mRNA Production: Leveraging synthetic DNA for enhanced IVT efficiency and rapid delivery"! 📅 Date: 28 August 🕒 Time: 12 PM ET (6 PM CEST).

Stick or twist? Exploring IBD drug target strategies in a saturated market: Differentiation is a key goal of any company. Never more so when entering a market that is already saturated, as is the case with IBD. Yet, 25 years after TNF-α inhibitor Remicade first received FDA approval in IBD, TNF-α is still by far the most common target in IBD preclinical and clinical studies. Considering there is still a large unmet need for IBD patients refractory to TNF-α based treatments, it seems reasonable to ask what do drug developers gain from continuing to pursue this target? Perhaps, in a complex condition like IBD, the lure of a tried and trusted clinically validated target is too much to ignore. Especially if there is a belief that safety and efficacy profiles can still be improved. Compared to the significant risks associated with establishing and proving a new target, maybe following a well-trodden path is the best way forward. Differentiation can be achieved in other ways after all. Follow our page for more life science market insights, or visit our website at: https://lnkd.in/e9yRCP4U If you need support with your market strategy, speak to the Hanson Wade Intelligence team at [email protected] #IBD #DrugDevelopment #PharmaInnovation #ClinicalResearch #Biotech #Pharmaceuticals #MedicalResearch #TNFInhibitors #HealthcareInnovation #BiotechStrategy #DrugTargets #PharmaIndustry #IBDTreatment #PharmaStrategy

Missed our live webinar on the latest in Inflammatory Bowel Disease (IBD) treatments? No worries! You can now watch it on demand. Catch up on all the insights into key drug modalities, recent approvals, market growth drivers, and more at your convenience. 🎥 Watch Now: https://ter.li/1rh5bs Stay informed and explore the cutting-edge developments driving the IBD market from Beacon Immune Tolerance and Hanson Wade Intelligence! #InflammatoryBowelDisease #IBD #JAKinhibitors #TNFalphas #S1Preceptors #DrugTrends #MarketAnalysis

🌟 Exciting Milestone in Cell Therapy! 🌟 The cell therapy space is buzzing with innovation and groundbreaking advancements, and we're thrilled to witness a historic moment: the first-ever approved engineered cell therapy for solid tumor indications by ?Adaptimmune! 🎉 This approval is a game-changer, marking a significant leap forward in the fight against solid tumors, which have long posed challenges in the realm of cell therapy. Adaptimmune's cutting-edge approach, harnessing the power of engineered T-cells, is not just a victory for science but a beacon of hope for countless patients battling these tough-to-treat cancers. As we continue to push the boundaries of what's possible in cell therapy, this achievement underscores the incredible potential of engineered cells to transform cancer treatment. The future is bright for this field, and we're only just beginning to scratch the surface of what these therapies can do. 🚀 Stay tuned for the latest development in cell therapy space with Hanson Wade Intelligence! #CellTherapy #CancerTreatment #Innovation #Biotech #Oncology #SolidTumors #Adaptimmune #HealthcareInnovation #MedicalBreakthrough

🌐🔬 Join our next webinar “Accelerating mRNA Production: Leveraging synthetic DNA for enhanced IVT efficiency and rapid delivery"! The event on the 28th of August is just around the corner. 📅 Date: 28 August 🕒 Time: 12 PM ET (6 PM CEST). 🌟 Hosted by Hanson Wade and Syngoi, featuring leading speakers from Syngoi Technologies, Quantoom Biosciences, Recipharm, Afrigen Biologics (Pty) Ltd 👩💼👨💼 Discover the latest innovations in mRNA production and how synthetic DNA technology is revolutionizing efficiency in Vitro Transcription (IVT). Register now to secure your spot! https://lnkd.in/dndj_KyW #Webinar #mRNAProduction #SyntheticDNA #Biotechnology #Innovation

What can publication date tell us about the allo vs. auto cell therapy space? Publication data is a fantastic way to assess temporal market trends. By taking a ‘snapshot’ of the market and benchmarking the yearly ‘ups’ and ‘downs’, you can infer whether the space is ‘hot’, or on the way out.  Here we examined whether the level of interest in the allo CT space is keeping up with its auto counterpart. And the answer is a clear ‘yes’ – despite the inherent additional safety and regulatory challenges, the potential prize of an ‘off-the-shelf’, cost-effective product is just too tempting to ignore. This simple way of seeing into the short- to medium-term future allows businesses to make smarter predictions and adapt strategy as needed. Follow our page for more cell therapy market insights, or visit our website at: https://lnkd.in/e9yRCP4U If you need support with your strategy planning, speak to the Hanson Wade Intelligence team at [email protected] #CellTherapy #MarketTrends #Biotech #CellTherapyTrends #HealthcareInnovation #Biopharma #RegenerativeMedicine #Oncology #Therapeutics #BiotechTrends #LifeSciences #MedicalInnovation #CellAndGeneTherapy #CGT

Myeloid Cell Therapies - A Differentiated Approach in a Crowded Market Myeloid cell therapies are starting to hit important milestones (just a month ago, another macrophage program – Resolution Therapeutics RTX001 – entered Phase 1/2 trials), so the Hanson Wade Intelligence team decided this was the perfect time to explore how myeloid cell therapy development compares to their lymphoid counterparts. Although the myeloid cell therapy landscape is small, the recent growth in pipeline clearly demonstrates the strong desire from the market to overcome existing lymphoid limitations, with the added benefit of ‘standing out from the crowd’. Macrophages lead the way due to their unique advantages in solid tumors - their superior infiltrating ability and broader array of anti-tumor mechanisms help offset the challenges caused by a scarcity of solid tumor targets. In addition, we assessed key competitor metrics and identified several high potential assets in this area, including MT-302. With a highly innovative in vivo RNA delivery approach and clinical readouts expected this year, this could be one to watch for the future! To stay ahead of the curve with indication landscapes, opportunity assessments, or other custom researches, visit our website at https://lnkd.in/e9yRCP4U Or Drop us an email at: [email protected] The analysis below was made possible with access to Beacon database. #MyeloidCellTherapy #CellTherapy #MacrophageTherapy #OncologyResearch #CancerTreatment #BiotechInnovation #Immunotherapy #BiotechTrends #SolidTumorTherapy #MedicalResearch #HealthcareInnovation #Biopharma #lifescience